Comparison of StemPrintER, a Novel Biology-based Genomic Predictor of Distant Recurrence in Breast Cancer, with Oncotype DX in the TransATAC cohort, shows that StemPrintER

  • Significantly (p<0.0001) stratifies high vs. low risk groups when adjusted for clinical parameters as expressed by clinical treatment scores (CTS)
  • Outperforms Oncotype DX in 10-year risk prediction in more than 800 ER+/HER2- postmenopausal breast cancer patients, including lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients
  • Adds more prognostic information than Oncotype DX on the top of clinical parameters as expressed by clinical treatment scores (CTS)
  • See poster | See abstract

Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer patients demonstrates that the next-generation StemPrintER Risk Score (SPARE) model is

  • approximately 20% superior to the traditional clinicopathological parameters, as expressed by the CTS, in providing prognostic information in more than 1,800 ER+/HER2- patients analyzed;
  • up to 40-50% more accurate in lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients.
  • Investigators found that SPARE added substantial prognostic information to CTS, but the inverse was not proven to be the case.
  • See poster | See abstract